Sign in
4

Changes in Ownership

Kalaris Therapeutics, Inc. Filed Acc 0000899243-21-003181

Chief Executive Officer acquired 147,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Hallal David · Chief Executive Officer

Table I: Non-derivative

1 line
Date Transaction Shares Owned after D/I
2021-01-21 Grant or award : show line 1 in the form +147,000 2,230,666 D

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2021-01-21 Grant or award : show line 2 in the form Stock Option (Right to Buy) +273,000 $45.04 2031-01-21 273,000 273,000 D
Loading xslF345X03/doc4.xml…